NERV
Minerva Neurosciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Minerva Neurosciences has 5 disclosed suppliers and 2 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceCommercial Supply Agreement by and between the Registrant and Catalent Germany Schorndorf GmbH, dated September 18, 2019
NERV 10-Kaccession 0001193125-26-101117
SentenceUnder the terms of the agreement, Catalent manufactures and packages the finished dose form of roluperidone at its facility in Schorndorf, Germany.
NERV 10-Kaccession 0001193125-26-101117
SentenceOn November 14, 2025, the Company entered into a consulting agreement (the "Consulting Agreement") with Dr. Inderjit Kaul, one of its directors.
NERV 10-Kaccession 0001193125-26-101117
SentenceIn addition, we are or have engaged with a number of consultants and companies, including Pharma Partnering in Research & Strategy SAS ("PPRS"), that provide expertise in the key functions involved with the development of our products.
NERV 10-Kaccession 0001193125-26-101117
SentenceOn October 11, 2022, the Company entered into an office lease agreement with Regus to lease office space located at 1500 District Avenue, Burlington, MA 01803.
NERV 10-Kaccession 0001193125-26-101117
SentenceIn January 2021, we sold our rights to these potential royalties to Royalty Pharma plc ("Royalty Pharma") for a $60 million cash payment and up to an additional $95 million in potential future milestone payments, subject to completion of Phase 3 trials by Janssen and regulatory approvals.
SentenceAs a result of our collaboration with Janssen, we were entitled to collect royalties in the mid-single digits on potential future worldwide sales of seltorexant in certain indications, with no further financial obligations to Janssen.
NERV 10-Kaccession 0001193125-26-101117
Minerva Neurosciences, Inc.
2.30
Linked news
Expected move
No implied move.